<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03566329</url>
  </required_header>
  <id_info>
    <org_study_id>N2011</org_study_id>
    <nct_id>NCT03566329</nct_id>
  </id_info>
  <brief_title>Magnesium Sulphate Versus Lidocaine for Control of Emergence Hypertension</brief_title>
  <official_title>Control of Emergence Hypertension After Craniotomy: Comparison Between the Efficacy of Magnesium Sulphate and Lidocaine Infusion (Randomized Controlled Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmed Mohamed ELbadawy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-craniotomy emergence hypertension is a common phenomenon that may predispose to
      development of intracranial hematoma and cerebral edema.The aim of this study is to compare
      the safety and efficacy of Mgso4 versus lidocaine infusion for control of emergence
      hypertension after craniotomy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postcraniotomy emergence hypertension response to the study drugs</measure>
    <time_frame>4hours</time_frame>
    <description>The number of the patients who have systolic blood pressure below 140 mmH during emergence of anesthesia after craniotomy for brain tumors in each group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery time</measure>
    <time_frame>2 hours</time_frame>
    <description>Time till discharge from PACU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of side effects of the used drugs</measure>
    <time_frame>4 hours</time_frame>
    <description>measure of safety</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Craniotomy</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Magnesium sulphate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg/kg over 10 minutes loading followed by 15mg/kg/hr infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lidocaine hydrochloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.5mg/kg loading followed by 2mg/kg/hr infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl 0.9% normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline infusion with the same rate as the study drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulphate</intervention_name>
    <description>Magnesium sulphate 50 mg/kg over 10 minutes loading followed by 15mg/kg/hr infusion. .</description>
    <arm_group_label>Magnesium sulphate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine Hydrochloride</intervention_name>
    <description>lidocaine hydrochloride 1.5mg/kg loading followed by 2mg/kg/hr infusion</description>
    <arm_group_label>lidocaine hydrochloride</arm_group_label>
    <other_name>Xylocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline infusion with the same rate of infusion as the study drugs</description>
    <arm_group_label>NaCl 0.9% normal saline</arm_group_label>
    <other_name>Nacl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status Ι or Π.

          -  scheduled patients for brain tumor excision.

        Exclusion Criteria:

          -  Hepatic, renal, cardiac, pulmonary, or endocrine impairment.

          -  Signs of increased intracranial pressure or allergy to any of the used drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed ELbadawy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of medicine- Cairo University- Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed ELbadawy, MD</last_name>
    <phone>01064249076</phone>
    <phone_ext>11562</phone_ext>
    <email>elbadawyahmed89@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ahmed ELbadawy</name>
      <address>
        <city>Cairo</city>
        <zip>02</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed ELbadawy</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 10, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2018</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed ELbadawy</investigator_full_name>
    <investigator_title>Ahmed Mohamed ELbadawy- Clinical investigator , Cairo University</investigator_title>
  </responsible_party>
  <keyword>craniotomy- Emergence- hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

